“Coronary artery ectasia (CAE)” is an uncommon kind of coronary heart disease that some people experience. It stands out due to its width being almost twice as larger than the healthy coronary artery next to it and its length being dilated by more than one-third. Positive stress tests, Angina pectoris, and acute coronary syndrome can all be signs of CAE in the absence of severe coronary constrictions. In an ectatic artery, thrombus development may be brought on by a vasospasm, distal embolization, or vascular rupture. Aspirin and other antiplatelet medications are the foundation of management for CAE. On the basis of occurrence of associated obstructive coronary artery condition and a patient's potential for bleeding, anticoagulants are utilized to prevent thrombus development. Hence those affected are encouraged to take statins as a primary preventative measure because the frequent cause of CAE is atherosclerosis. “Angiotensin-converting enzyme (ACE)” inhibitors may be administered to people with elevated blood pressure due to their anti-inflammatory characteristics. Calcium channel blockers and Beta-blockers may be helpful if hypertension and coronary vasospasm co-occur. Nitrates are typically not advised because they could make symptoms worse. The avoidance of thromboembolic consequences and surgical or percutaneous revascularization are additional CAE therapeutic options. The linked coronary artery's severity affects the CAE prognosis.